| # | Title | Journal | Year | Citations |
|---|
| 1 | SPIKES—A Six‐Step Protocol for Delivering Bad News: Application to the Patient with Cancer | Oncologist | 2000 | 2,157 |
| 2 | FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma | Oncologist | 2007 | 1,142 |
| 3 | Impact of Cancer‐Related Fatigue on the Lives of Patients: New Findings From the Fatigue Coalition | Oncologist | 2000 | 1,048 |
| 4 | The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti–HER-2 Therapy and Personalized Medicine | Oncologist | 2009 | 986 |
| 5 | Cancer Statistics, Trends, and Multiple Primary Cancer Analyses from the Surveillance, Epidemiology, and End Results (SEER) Program | Oncologist | 2007 | 889 |
| 6 | Management of Cancer in the Older Person: A Practical Approach | Oncologist | 2000 | 857 |
| 7 | The Financial Toxicity of Cancer Treatment: A Pilot Study Assessing Out-of-Pocket Expenses and the Insured Cancer Patient's Experience | Oncologist | 2013 | 834 |
| 8 | The Incidence and Epidemiology of Hepatocellular Carcinoma: A Global and Regional Perspective | Oncologist | 2010 | 817 |
| 9 | Dual Kinase Inhibition in the Treatment of Breast Cancer: Initial Experience with the EGFR/ErbB‐2 Inhibitor Lapatinib | Oncologist | 2004 | 737 |
| 10 | Cancer‐Related Fatigue: The Scale of the Problem | Oncologist | 2007 | 713 |
| 11 | The Role of ABC Transporters in Clinical Practice | Oncologist | 2003 | 708 |
| 12 | The Role of Hypoxia‐Induced Factors in Tumor Progression | Oncologist | 2004 | 684 |
| 13 | The Differential Efficacy of Pemetrexed According to NSCLC Histology: A Review of Two Phase III Studies | Oncologist | 2009 | 669 |
| 14 | Triple-Negative Breast Cancer: An Unmet Medical Need | Oncologist | 2011 | 636 |
| 15 | Photodynamic Therapy in Oncology | Oncologist | 2006 | 632 |
| 16 | FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome | Oncologist | 2018 | 631 |
| 17 | Frequent Mutation of Isocitrate Dehydrogenase (IDH)1 and IDH2 in Cholangiocarcinoma Identified Through Broad-Based Tumor Genotyping | Oncologist | 2012 | 629 |
| 18 | Obesity and Cancer | Oncologist | 2010 | 628 |
| 19 | Tumor Hypoxia: Causative Factors, Compensatory Mechanisms, and Cellular Response | Oncologist | 2004 | 625 |
| 20 | TNF‐α in Cancer Treatment: Molecular Insights, Antitumor Effects, and Clinical Utility | Oncologist | 2006 | 624 |
| 21 | Changes in Survival in Head and Neck Cancers in the Late 20th and Early 21st Century: A Period Analysis | Oncologist | 2010 | 623 |
| 22 | Biology and Therapeutic Advances for Pediatric Osteosarcoma | Oncologist | 2004 | 604 |
| 23 | The Clinical Approach Towards Chondrosarcoma | Oncologist | 2008 | 602 |
| 24 | Understanding and Managing Methotrexate Nephrotoxicity | Oncologist | 2006 | 591 |
| 25 | The NOMS Framework: Approach to the Treatment of Spinal Metastatic Tumors | Oncologist | 2013 | 570 |
| 26 | Velcade ® : U.S. FDA Approval for the Treatment of Multiple Myeloma Progressing on Prior Therapy | Oncologist | 2003 | 562 |
| 27 | The HER‐2/ neu Gene and Protein in Breast Cancer 2003: Biomarker and Target of Therapy | Oncologist | 2003 | 561 |
| 28 | Extending Survival with Chemotherapy in Metastatic Breast Cancer | Oncologist | 2005 | 556 |
| 29 | Preventing and Managing Toxicities of High-Dose Methotrexate | Oncologist | 2016 | 550 |
| 30 | FDA Drug Approval Summary: Bevacizumab (Avastin®) as Treatment of Recurrent Glioblastoma Multiforme | Oncologist | 2009 | 548 |
| 31 | Forty-Year Trends in Cholangiocarcinoma Incidence in the U.S.: Intrahepatic Disease on the Rise | Oncologist | 2016 | 548 |
| 32 | A Practical Approach to the Management of Cancer Patients During the Novel Coronavirus Disease 2019 (COVID-19) Pandemic: An International Collaborative Group | Oncologist | 2020 | 520 |
| 33 | FDA Drug Approval Summary: Gefitinib (ZD1839) (Iressa ® ) Tablets | Oncologist | 2003 | 515 |
| 34 | Vascular Endothelial Growth Factor as a Target for Anticancer Therapy | Oncologist | 2004 | 511 |
| 35 | Beyond Costs and Benefits: Understanding How Patients Make Health Care Decisions | Oncologist | 2010 | 511 |
| 36 | Interferon in Oncological Practice: Review of Interferon Biology, Clinical Applications, and Toxicities | Oncologist | 2001 | 478 |
| 37 | Topotecan in the Treatment of Recurrent Small Cell Lung Cancer: An Update | Oncologist | 2004 | 478 |
| 38 | Prognostic and Predictive Factors in Early‐Stage Breast Cancer | Oncologist | 2004 | 476 |
| 39 | Systematic Review of Medical Treatment in Melanoma: Current Status and Future Prospects | Oncologist | 2011 | 472 |
| 40 | VEGF Receptor Signaling in Tumor Angiogenesis | Oncologist | 2000 | 460 |
| 41 | Molecular Characterization of Basal-Like and Non-Basal-Like Triple-Negative Breast Cancer | Oncologist | 2013 | 454 |
| 42 | The Oncosurgery Approach to Managing Liver Metastases from Colorectal Cancer: A Multidisciplinary International Consensus | Oncologist | 2012 | 453 |
| 43 | Molecular Stratification of Triple-Negative Breast Cancers | Oncologist | 2011 | 452 |
| 44 | Mechanisms of Cancer‐Related Fatigue | Oncologist | 2007 | 447 |
| 45 | The Etiology of Hepatocellular Carcinoma and Consequences for Treatment | Oncologist | 2010 | 437 |
| 46 | Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor | Oncologist | 2015 | 436 |
| 47 | FDA Drug Approval Summary: Azacitidine (5‐azacytidine, Vidaza ™ ) for Injectable Suspension | Oncologist | 2005 | 432 |
| 48 | Epidermal Growth Factor Receptor Dependence in Human Tumors: More Than Just Expression? | Oncologist | 2002 | 424 |
| 49 | Ewing's Sarcoma Family of Tumors: Current Management | Oncologist | 2006 | 424 |
| 50 | Why the Epidermal Growth Factor Receptor? The Rationale for Cancer Therapy | Oncologist | 2002 | 419 |
